ALK-driven tumors develop in ~3–8% of patients with NSCLC, and development of these tumors is associated with important patient features: more than 90% of these patients have never smoked or had only light smoking habits, were female, younger at diagnosis, where diagnosed with adenocarcinoma by histology, and lacked other oncogenic drivers [2, 3]. The gene discussed is ALK; the disease is adenocarcinoma.